INS and type 2 diabetes mellitus: The intraventricular injection of FGF19 can increase phosphorylated AKT levels in the liver, quadriceps, and white adipose tissue, suggesting that FGF19 can enhance insulin sensitivity, indicating that it may represent a potential drug for the treatment of type 2 diabetes (Marcelin et al., 2014).